# Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study

> **NCT01849068** · PHASE3 · COMPLETED · sponsor: **Laval University** · enrollment: 20 (actual)

## Conditions studied

- Metabolic Syndrome X

## Interventions

- **DRUG:** Ezetimibe
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01849068
- **Lead sponsor:** Laval University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-06
- **Final completion:** 2016-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01849068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01849068, "Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01849068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*